On Jul 7, 2021 Adial Pharmaceuticals closed a private placement of 700,001 shares of common stock and raised $5,000,000 from Bespoke Growth Partners, Keystone Capital Partners, Richard Gilliam, featuring lead investors Bespoke Growth Partners.

About the company: Adial Pharmaceuticals is located in the United States, North America. “Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.”

Company website: adialpharma.com